A differential 5hmC gene body analysis between disease states identified genes in proliferative pathways to have a progressive increase in 5hmC levels during tumor progression, which was also observed for oncogenic pathways, such as MYC targets and E2F targets (Fig. 2B). The gene discussed is MYC; the disease is neoplasm.